Signal transduction inhibitors as novel anticancer drugs: where are we?
Workman
P
P
CRC Department of Medical Oncology, University of Glagow, Scotland.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D054713:Bryostatins; D002453:Cell Cycle; D006801:Humans; D007783:Lactones / Q000494:pharmacology; D018942:Macrolides; D009857:Oncogenes; D011493:Protein Kinase C / Q000502:physiology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects*
D000970:Antineoplastic Agents; D054713:Bryostatins; D007783:Lactones; D018942:Macrolides; C046785:bryostatin 1; D011505:Protein-Tyrosine Kinases; D011493:Protein Kinase C